Margin inflection, a new CFO, and a $1B dip-buy: Cencora makes the reacceleration 'mechanical'

OneOncology remakes the P&L mix, biosimilar/Part B conviction hardens against new ASP-340B policy, and the new CFO signals capital discipline into a drawdown

COR · Earnings Call · 2026-08-05

A reacceleration wrapped in continuity

Cencora's fiscal Q3 print was framed by management as the payoff of a planned ramp. Consolidated adjusted operating income rose 17%, EPS rose 12%, and the company raised full-year EPS guidance to $17.75–$17.95. The heart of the beat was the U.S. Healthcare Solutions segment, whose operating income grew 16% to $966M and, “excluding the loss ... of Florida Cancer and the contribution from OneOncology, our operating income growth was up double digits, a meaningful acceleration from the 7% last quarter” — Eva Boratto, Chief Financial Officer · 2026-08-05. That acceleration directly answers the question analysts posed on the May call, when Jim Cleary had to walk through $10M weather and COVID-vaccine headwinds to defend 7% core growth (“We saw a $10 million operating income headwind related to weather and specialty practices ... we did see the business rebound in March and saw good trends in April” — James Cleary, Executive Vice President and Chief Financial Officer · 2026-05-06). CEO Bob Mauch was even blunter about why Q2 was the trough: “It was mechanical, not aspirational” — Robert Mauch, President and CEO · 2026-08-05. What makes this more than a beat-and-raise is the mix shift underneath it. The MSO platform, anchored by OneOncology (acquired in February) and RCA, is fatter-margin than distribution, and it is visibly tilting the whole P&L. Filings through the April quarter show operating margin reached 2.7%, up about 1.3 points year-over-year — the clearest confirmation yet of the inflection point George Hill probed on the November 2025 call, when Jim Cleary argued “the MSO strategy is the natural evolution of our highly successful specialty business that offers more services, of course, that is accretive to our margins also” — James Cleary, Chief Financial Officer · 2025-11-05.

The Part B conviction, now field-tested by policy

The most consequential new theme on the call was regulatory. Kevin Caliendo asked about proposed ASP rule changes, and Bob Mauch's answer was a carefully constructed defense of physician reimbursement, name-dropping the GLOBE demonstration project: “any discounts that are paid from the manufacturer to the government actually are not going to flow through reimbursement or impact ASP” — Robert Mauch, President and CEO · 2026-08-05. This is the 340B program test and ASP debate arriving in Cencora's lane, and management leaned on a broader argument — that policymakers won't risk harming physician reimbursement in the community setting. It also sharpened the biosimilar thesis, which splits cleanly between Part D (revenue pressure, minimal profit) and Part B (profit tailwind because of wraparound services):

When we think about the Part B buy-and-bill infusion space... we play a bigger role in how they're assessed and utilized... Part B will always be good, and we feel very confident about the durability of that over the long term.
Robert Mauch, President and CEO · 2026-08-05

That Biosimilars conviction is what underpins the long-term guidance Cencora kept intact, even while flagging a ~$0.35 EPS headwind in fiscal 2027 if the MWI/Covetrus deal closes mid-year.

MSO innings and the logistics turnaround

The MSO thesis was also given a maturity timeline. On clinical trials, Bob described RCA as “in the later innings of the build-out” — Robert Mauch, President and CEO · 2026-08-05 while OneOncology is “in the earlier innings” — Robert Mauch, President and CEO · 2026-08-05 — which is exactly why the platform still has headroom, plus a pipeline of tuck in acquisitions in retina and oncology only. Meanwhile, International — long the drag — delivered 21% operating income growth, powered by what Eva Boratto called “strong renewals ... that have supported new business wins” — Eva Boratto, Chief Financial Officer · 2026-08-05 in World Courier and European 3PL. The keyword motion here is telling: “logistics business” and “World Courier” have fallen out of the company's top keywords after years of being a problem — the market's attention moved on precisely as the business stabilized.

Leadership, capital, and the timing of the buyback

This was also the debut of Eva Boratto as CFO, and her messaging on capital deployment (internal investment, strategic M&A, opportunistic buybacks, dividend growth) was deliberately continuous with the prior regime. The confirmation: Cencora repurchased $1B of stock in the quarter at an average of $268/share — a well-timed dip-buy given the shares had been in a ~15% drawdown since the November 2025 peak (the whole-history tape shows peak $374.75 on 2025-11-25, DD -15.1%). The stock has since recovered toward $318, so the buyback sits nicely in the money. One caution from the balance sheet: net debt ballooned to ~$10.1B net effective cash as the OneOncology deal was funded, and free cash flow is tracking below last year — the $3B FY guidance is intact but there is less cushion than the pharmaceutical centric narrative implies. Contextually, Cencora fits comfortably into this quarter's broader Earnings growth theme — the global keyword tower's #2 idea — while remaining an outlier in one important way: peers across the tape are booking tariff refunds (BRKR, DORM, HBB, MSI, many more), but COR keeps pointing out that drug manufacturers are the importers of record, so tariffs largely pass them by. That insulation, plus the Part B biosimilar tailwind, is why the reacceleration reads as structural rather than episodic — and why the real swing factor going forward is not utilization but whether the ASP/340B policy debate ends up touching the economics that make the model work.